The natural history of Parkinson’s disease

@article{Poewe2006TheNH,
  title={The natural history of Parkinson’s disease},
  author={W. Poewe},
  journal={Journal of Neurology},
  year={2006},
  volume={253},
  pages={vii2-vii6}
}
  • W. Poewe
  • Published 2006
  • Medicine
  • Journal of Neurology
Although Parkinson’s disease (PD) is the only chronic neurodegenerative disorder for which there are effective symptomatic therapies no treatment has yet been identified that would significantly slow its natural progression. Studies into the natural history of Parkinson’s disease have been complicated by issues of diagnostic accuracy, heterogeneity of different forms of the disease as well as confounding effects of age related comorbidities.Only recently results from placebo-controlled clinical… Expand
The factor structure of the UPDRS as an index of disease progression in Parkinson's disease.
TLDR
Invest exploratory factor analysis (EFA) indicates that the UPDRS captures meaningful aspects of disease progression in PD, and that it is possible to identify symptom/sign complexes which evolve independently of one another. Expand
Early Parkinson’s Disease. Incidence, clinical features and quality of life in a population-based cohort study.
TLDR
All cases of incident PD from the Norwegian counties Sogn og Fjordane, Hordaland, Rogaland and Aust-Agder, comprising a base-population of about 1 million inhabitants were recruited and cases with probable PD were invited to further examinations and longitudinal follow-up. Expand
Parkinson ’ s Disease and Quality of Life – A Clinician ’ s Perspective
In Parkinson’s disease (PD) the quality of life (QoL) of a patient is adversely affected by both the motor and non-motor symptoms of the disease. The fact that QoL is reduced in the early stages ofExpand
Assessment of disease progression and functional benefit in neurodegenerative disease: Can we tell the difference?
TLDR
This review summarizes recent trials in ALS and Parkinson's disease, with the goal of increasing understanding of how the choice of outcome measures influences what can be concluded from the results. Expand
The Importance of Rehabilitation Treatment in Patients with Parkinson’s Disease
TLDR
Rehabilitation programs contain kinesiotherapeutic procedures for balance, posture, the range of motionsespecially rotation of the trunk, strength, elongation, as well as exercise for functionally reduced motion types. Expand
Cognitive and Psychiatric Aspects of Parkinson’s Disease
TLDR
For this chapter the literature on some factors of non-motor aspects of PD has been reviewed and is summarized here. Expand
Clinical neuroprotection in Parkinson's disease — Still waiting for the breakthrough
TLDR
The need for neuroprotective therapies in PD is explained, results and limitations of previous clinical trials are discussed, and some food for thought is provided for the future research of neuroprotection in PD. Expand
Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling.
TLDR
These longitudinal results support the differentiation of apathy and depression in PD and suggest that apathy progression may be linked at least partially to dopaminergic neurodegeneration. Expand
Statistical Models of Parkinson's Disease Progression: Predictive Validity in a 3-Year Follow-up.
TLDR
A cross-sectional assessment of a PD population allowed the development of regression-based models of disease progression, whose predictive value was validated on a three-year longitudinal study. Expand
Parkinson disease and exercise.
TLDR
Exercise is currently an area receiving substantial research attention as investigators seek interventions that may modify the progression of the disease, perhaps through neuroprotective mechanisms. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease
TLDR
Previous studies suggesting better outcome of tremor-dominant than akinetic-rigid type of PD, significantly worse outcome in PD with late onset and dementia that is significantly correlated with coexistent neuritic Alzheimer pathology, particularly when using the CERAD and NIA-R criteria for the diagnosis of AD are confirmed. Expand
Levodopa and the progression of Parkinson's disease.
TLDR
The clinical data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease, and the neuroimaging data suggest either thatlevodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine transporter. Expand
Clinical observations on the rate of progression of idiopathic parkinsonism.
TLDR
It is concluded that age and duration of symptoms influence the natural history of IP additively and independently and the rate of neuronal death is more rapid in the earlier stages of evolution of the pathology; subsequently, the velocity of progression slows down to approach the rates of attrition produced by normal ageing. Expand
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
TLDR
Coenzyme Q10 appears to slow the progressive deterioration of function in PD, but these results need to be confirmed in a larger study. Expand
Idiopathic hyposmia as a preclinical sign of Parkinson's disease
TLDR
Results indicate that idiopathic olfactory dysfunction is associated with an increased risk of developing PD of at least 10%. Expand
The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years
TLDR
Mortality in Parkinson’s disease remains increased despite low dose levodopa- carbidopa-carbidopa therapy and no additional benefit was gained from early use of bromocriptine. Expand
Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.
TLDR
Investigation of the prevalence of dyskinesias and motor fluctuations in a community-based population of patients with Parkinson's disease concludes that motor fluctuations are most strongly related to disease duration and dose of levodopa, and dysKinesias to duration oflevodopa treatment. Expand
Parkinsonism: onset, progression, and mortality
TLDR
Controversy over the effectiveness of therapeutic measures for parkinsonism is due partially to this wide variability and to the paucity of clinical information about the natural history of the syndrome. Expand
Frequency of bowel movements and the future risk of Parkinson’s disease
TLDR
Infrequent bowel movements are associated with an elevated risk of future PD, and further study is needed to determine whether constipation is part of early PD processes or is a marker of susceptibility or environmental factors that may cause PD. Expand
Association between early-onset Parkinson's disease and mutations in the parkin gene.
TLDR
Mutations in the parkin gene are a major cause of early-onset autosomal recessive familial Parkinson's disease and isolated juvenile-ONSet Parkinson's Disease and accurate diagnosis of these cases cannot be based only on the clinical manifestations of the disease. Expand
...
1
2
3
...